Characteristics of Smoking Patients with Lung Cancer with Emphysematous Bullae Eiji Iwama, MD, PhD, Isamu Okamoto, MD, PhD, Hidetake Yabuuchi, MD, PhD,

Slides:

Advertisements

Similar presentations

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Advertisements

Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?: A Pooled.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer Timothy R. Wassenaar, MD, Jens C.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

SC17.02 Lung Cancer in China: Challenges and Perspectives

Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?: A Pooled.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Electronic Updates for JTO Readers

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer Timothy R. Wassenaar, MD, Jens C.

Boundary between N1 and N2 Lymph Node Descriptors in the Subcarinal Zone in Lower Lobe Lung Cancer: A Brief Report Mitsuhiro Isaka, MD, Haruhiko Kondo,

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease Masayuki Takeda, MD, PhD, Isamu Okamoto, MD, PhD, Chihiro.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition Sai-Hong.

Histology and Smoking Status Predict Survival of Patients with Advanced Non–Small- Cell Lung Cancer: Results of West Japan Oncology Group (WJOG) Study.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Pharmacokinetics of Gefitinib Predicts Antitumor Activity for Advanced Non-small Cell Lung Cancer Yoichi Nakamura, MD, PhD, Kazumi Sano, PhD, Hiroshi.

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6 Paul J. Hesketh, MD, Rogerio C. Lilenbaum,

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Clinicopathological Characteristics of Screen-Detected Lung Cancers

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Four-Year Complete Remission in a Patient with Metastatic Epidermal Growth Factor Receptor–Mutated Lung Cancer Treated with Two Cycles of Erlotinib Brendan.

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Nasion Swelling as the Presenting Symptom of Lung Adenocarcinoma

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

A Primer on Health Economic Evaluations in Thoracic Oncology

Dose-per-Fraction Escalation of Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy in Locally Advanced Non-small Cell Lung Cancer

Alectinib for Patients with ALK Rearrangement–Positive Non–Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401)

Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in.

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

It’s All in the “Swerve of the Curve”

Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor–Resistant Non–Small Cell Lung Cancer Hiroaki Ogata,

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Two Generations of Light/Never-Smokers With Advanced Adenocarcinoma of the Lung with Durable Responses to Erlotinib Nathan A. Pennell, MD, PhD, Lihong.

Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD, Yasunori Sohara, MD, Ryosuke Tsuchiya, MD,

Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?

Significance of Smoking as a Postoperative Prognostic Factor in Patients with Non- small Cell Lung Cancer Takeshi Hanagiri, MD, PhD, Kenji Sugio, MD,

Clinical and Pathological Staging Validation in the Eighth Edition of the TNM Classification for Lung Cancer: Correlation between Solid Size on Thin-Section.

International Thymic Malignancies Interest Group: A Way Forward

European Lung Cancer Conference (ELCC) 2016 Organisation

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping Wei Jin, MD, Benjie Shan, MD, Hu Liu, PhD, Shoubing Zhou, PhD, Wenjuan.

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Palliative Thoracic Radiotherapy in Locally Advanced Non-small Cell Lung Cancer: Can Quality-Of-Life Assessments Help in Selection of Patients for Short-

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Robert Comis, MD, The Passing of a “Lung Man”

Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues” Boris Sepesi,

Presentation transcript:

Characteristics of Smoking Patients with Lung Cancer with Emphysematous Bullae Eiji Iwama, MD, PhD, Isamu Okamoto, MD, PhD, Hidetake Yabuuchi, MD, PhD, Koichi Takayama, MD, PhD, Taishi Harada, MD, PhD, Yoshio Matsuo, MD, PhD, Shoji Tokunaga, PhD, Eishi Baba, MD, PhD, Yoichi Nakanishi, MD, PhD Journal of Thoracic Oncology Volume 11, Issue 9, Pages 1586-1590 (September 2016) DOI: 10.1016/j.jtho.2016.04.024 Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Overall survival according to the absence or presence of emphysematous bullae in patients with advanced lung cancer who were smokers and treated with chemotherapy. MST, median survival time. Journal of Thoracic Oncology 2016 11, 1586-1590DOI: (10.1016/j.jtho.2016.04.024) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Representative computed tomography images of primary lung cancer in areas adjoining emphysematous bullae (EBs) (A) or apart from EBs (B). Arrowhead and arrows indicate primary lung cancer and EBs, respectively. Journal of Thoracic Oncology 2016 11, 1586-1590DOI: (10.1016/j.jtho.2016.04.024) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions